Leap therapeutics, inc. (LPTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-7,231

-7,996

-7,935

-8,366

-8,603

1,480

-6,632

-7,364

-10,622

-6,593

-6,815

-6,905

-9,414

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

10

10

12

13

12

12

13

12

12

13

10

0

25

Amortization of contract asset

34

-

-

-

-

-

-

-

-

-

-

-

-

Amortization on right-of-use asset

191

-

-

-

177

-

-

-

-

-

-

-

-

Stock-based compensation expense

570

936

950

899

947

925

932

884

728

695

649

633

3,623

Foreign currency loss

991

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of restricted stock liability

-159

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense - related party

-

-

-

-

-

-

-

-

-

0

0

0

121

Change in fair value of warrant liability

-

-

-

-

-

-11,004

-1,793

662

4,851

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-362

-22

-271

34

-43

182

-455

453

117

-49

14

64

70

Research and development incentive receivable

86

-771

-11

64

75

-1,260

312

257

-89

-140

-2,209

494

397

Contract acquisition costs

270

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-770

-

-424

361

780

-

-115

463

-419

-42

1,604

-232

-237

Deferred revenue

2,625

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability

-193

-

-185

-172

-149

-

-

-

-

-

-

-

-

Net cash used in operating activities

-3,926

-5,894

-6,957

-7,183

-6,868

-7,050

-7,452

-6,053

-5,478

-6,369

-2,357

-7,062

-6,349

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

0

-2

1

65

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

0

2

-1

-65

Cash flows from financing activities:
Proceeds from issuance of common stock in connection with merger with Macrocure

-

-

-

-

-

-

-

-

-

0

0

0

21,165

Proceeds from issuance of common stock

-

-

-

-

12,331

-

-

-

-

0

0

0

10,000

Proceeds from the issuance of common stock, net of underwriter commissions and discounts

-

-

-

-

-

0

0

1

15,033

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

0

750

Proceeds from the exercise of common stock warrants

128

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

11

-

-

-

-

-

-

-

-

-

-

-

-

Payment of deferred offering costs

1,520

20

362

46

9

40

81

210

28

105

0

0

2,067

Net cash provided by financing activities

25,605

-19

1,254

1,260

12,322

-40

-67

1,008

15,005

17,895

0

20

29,848

Effect of exchange rate changes on cash and cash equivalents

-105

-269

14

61

-29

125

287

150

112

8

-613

414

-427

Net increase in cash and cash equivalents

21,574

-6,167

-5,689

-5,962

5,425

-6,965

-7,232

-4,895

9,639

11,534

-2,968

-6,629

23,007

Supplemental disclosure of non-cash financing activities:
Reclassification of 2017 warrants from liability to equity

-

-

-

-

3,448

-

-

-

-

-

-

-

-

Accretion of preferred stock to redemption value

-

-

-

-

-

-

-

-

-

0

0

0

244

Dividend attributable to down round feature of warrants

303

0

0

0

359

-

-

-

-

-

-

-

-

Offering costs included in accounts payable and accrued expenses

144

-

-

-

213

-

-

-

210

-

-

-

-

Right-of-use asset recorded upon adoption of ASU 2016-02

-

0

0

0

1,755

-

-

-

-

-

-

-

-

Lease liability recorded upon adoption of ASU 2016-02

-

0

0

0

1,720

-

-

-

-

-

-

-

-

Accrued rent reclassified upon adoption of ASU 2016-02

-

0

0

0

35

-

-

-

-

-

-

-

-

Conversion of Series A Convertible Preferred Stock to prefunded warrants

8,836

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of notes payable-related party and accrued interest convertible preferred stock into common stock

-

-

-

-

-

-

-

-

-

0

0

0

31,145

Conversion of Series B Convertible Preferred Stock to common stock

7,088

-

-

-

-

-

-

-

-

-

0

0

70,775

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

9,399

-

-

-

-

-

-

-

-

-

-

-

-

Value of net assets acquired in connection with merger with Macrocure, excluding cash

-

-

-

-

-

-

-

-

-

0

0

0

96

Series A Convertible Preferred Stock
Proceeds from the issuance of Series convertible preferred stock

14,986

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series A Convertible Preferred Stock to prefunded warrants

-8,836

-

-

-

-

-

-

-

-

-

-

-

-

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

-5,226

-

-

-

-

-

-

-

-

-

-

-

-

Series B Convertible Preferred Stock
Proceeds from the issuance of Series convertible preferred stock

12,000

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series B Convertible Preferred Stock to common stock

-7,087

-

-

-

-

-

-

-

-

-

-

-

-

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

-4,173

-

-

-

-

-

-

-

-

-

-

-

-